ROCHESTER, NEW YORK - Syntec Optics Holdings, Inc. (NASDAQ:OPTX), known for its work in scientific instruments and aerospace, has announced a significant step forward in vision restoration technology. The company is now developing optics that can be integrated with a bioengineered artificial cornea, aimed at patients undergoing clinical trials for blindness in the U.S.
The artificial cornea designed by Syntec Optics' customer is intended to replace the need for human tissue in corneal transplants. This innovation comes at a critical time as there is a shortage of human tissue for transplants, with many patients unable to access compatible tissue.
According to reports, the artificial cornea has already restored sight to individuals abroad who were blind for decades and had previously rejected human tissue transplants.
Joe Mohr, CEO of Syntec Optics, expressed enthusiasm about the potential impact of this technology, noting that patients have been able to read text and recognize family members post-implant. He emphasized the role of biomimicry in creating these artificial products, which could provide new possibilities for those suffering from long-term vision loss due to corneal damage.
Syntec Optics, with over two decades of experience, is a major player in the custom optics and photonics manufacturing industry in the United States. The company has recently expanded its product offerings to include optics for Low Earth Orbit satellites, night vision goggles, biomedical equipment, and precision microlens arrays.
The information provided here is based on a press release statement and is intended to inform about Syntec Optics' latest advancement in optics for artificial corneas.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.